Orthocell Ltd's (ASX:OCC) Paul Anderson says the company's in an exciting regulatory phase having validated its technologies in the clinic and defining pathways to market through the US FDA process. ''We have some significant milestones ahead of us - we have an application within the FDA at the moment for our bone application for CelGro and we've followed that up with an application into the Australian marketplace''. ''We're very soon to begin a preclinical animal study which will help us get our nerve product into the US market as well and we're also following that up with an Australian application''. Last week Orthocell had the positive pre-clinical and clinical results for the use of CelGro® in enhancing repair of critical bone defects published in the highly regarded Tissue Engineering journal.
Orthocell 'in exciting regulatory phase' as it looks to drive its technologies into the US market
Quick facts: Orthocell Ltd
Price: 0.36 AUD
Market Cap: $66.52 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE